Anika Therapeutics (NASDAQ:ANIK) posted its earnings results on Thursday. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.33), MarketWatch Earnings reports. Anika Therapeutics had a net margin of 7.17% and a return on equity of 8.06%. The firm had revenue of $30.68 million for the quarter, compared to analysts’ expectations of $16.73 million.

Shares of Anika Therapeutics stock opened at $36.40 on Friday. Anika Therapeutics has a twelve month low of $22.01 and a twelve month high of $75.71. The firm’s 50-day moving average price is $35.53 and its 200 day moving average price is $36.02. The company has a current ratio of 6.15, a quick ratio of 4.81 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $516.81 million, a PE ratio of 22.61, a P/E/G ratio of 6.74 and a beta of 1.18.

In other Anika Therapeutics news, EVP James Loerop sold 1,244 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $35.15, for a total transaction of $43,726.60. Following the completion of the transaction, the executive vice president now owns 3,000 shares of the company’s stock, valued at $105,450. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.53% of the stock is currently owned by insiders.

ANIK has been the topic of several analyst reports. Zacks Investment Research upgraded shares of Anika Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 8th. Barrington Research lowered Anika Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Friday, May 8th. BidaskClub downgraded Anika Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 15th. Finally, ValuEngine raised Anika Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Anika Therapeutics presently has a consensus rating of “Hold” and an average price target of $50.40.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.

Featured Article: Do Tariffs Work?

Earnings History for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with's FREE daily email newsletter.